, World Health Organisation. Global Tuberculosis Report, p.214, 2016.
Prevalent and Incident Tuberculosis Are Independent Risk Factors for Mortality among Patients Accessing Antiretroviral Therapy in South Africa, PLoS One, vol.8, 2013. ,
Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis, AIDS, vol.29, pp.1987-2002, 2015. ,
, Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Geneva: World Health Organisation, 2011.
Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study, Lancet, vol.377, 2011. ,
Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: What lessons have we learnt and how can we do better?, Eur Respir J, vol.2016, pp.543-2016, 2016. ,
Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study, Lancet Infect. Dis, vol.18, pp.76-84, 2018. ,
Evaluation of the 2007 WHO guideline to improve the diagnosis of tuberculosis in ambulatory HIV-positive adults, PLoS One, vol.6, 2011. ,
Validation in Uganda of the New WHO Diagnostic Algorithm for SmearNegative Pulmonary Tuberculosis in HIV Prevalent Settings, J Acquir Immune Defic Syndr, vol.15, issue.5, pp.93-100, 2011. ,
Performance of the 2007 WHO algorithm to diagnose smear-negative pulmonary tuberculosis in a HIV prevalent setting, PLoS One, vol.7, 2012. ,
Xpert® MTB/ RIF assay for pulmonary tuberculosis and rifampicin resistance in adults ,
, Database Syst Rev, 2014.
Metaanalysis to compare the accuracy of GeneXpert, MODS and the WHO 2007 algorithm for diagnosis of smear-negative pulmonary tuberculosis, BMC Infect Dis, vol.13, p.507, 2013. ,
Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings?, Lancet Infect Dis, pp.527-559, 2014. ,
Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial, Lancet, vol.383, pp.424-459, 2014. ,
Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: a pragmatic randomised trial, PLoS Med, vol.11, 2014. ,
Impact of replacing smear microscopy with Xpert MTB/ RIF for diagnosing tuberculosis in Brazil: a stepped-wedge clusterrandomized trial, PLoS Med, vol.11, 2014. ,
Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: A cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF, Lancet Glob. Heal, vol.3, pp.450-457, 2015. ,
Empiric TB treatment of severely ill patients with HIV and presumed pulmonary TB improves survival, JAIDS J Acquir Immune Defic Syndr, vol.72, 2016. ,
Empiric Tuberculosis Therapy versus Isoniazid in Advanced HIV-infected Adult Outpatients Initiating Antiretroviral Therapy: a Multi-Country Randomized Controlled Trial, Lancet, vol.387, pp.1198-209, 2016. ,
High mortality in adults hospitalized for active tuberculosis in a low HIV prevalence setting, PLoS One, vol.18, issue.3, p.92077, 2014. ,
Treatment decisions and mortality in HIV-positive presumptive smear-negative TB in the Xpert® MTB/RIF era: a cohort study ,
, Dis, vol.17, p.433, 2017.
Impact of three empirical anti-tuberculosis treatment strategies for people initiating antiretroviral therapy, Int J Tuberc. Lung Dis, vol.18, pp.1340-1346, 2014. ,
Added value of including Xpert MTB/RIF in an algorithm to diagnose smear-negative tuberculosis in a HIV prevalent resource-constraint setting, Union world Conf. Lung heal, 2014. ,
, Nairobi: National Tuberculosis Leprosy and Lung Diseases Program, 2014.
, Ministry of Health. Kenya HIV estimates. Nairobi: Ministry of Health, 2014.
Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents. Recommendations for HIV-prevalent and resourceconstrained settings. Geneva: World Health Organisation, Int J Tuberc Lung Dis, vol.3, pp.138-180, 1999. ,
, Xpert MTB/RIF implementation manual. Geneva: World Health Organization, 2014.
Empirical treatment for TB in HIV: lessons from a cohort study of people living with HIV treated in Recife, Brazil, BMC Public Health, vol.14, p.289, 2014. ,
Potential utility of empirical tuberculosis treatment for HIV-infected patients with advanced immunodeficiency in high TB-HIV burden settings, Int J Tuberc Lung Dis, vol.15, pp.287-95, 2011. ,
Systematic vs test-guided tuberculosis treatment: data of the statis randomized trial, CROI, editor. Conf. Retroviruses Opportunistic Infect, 2018. ,